Previously, we reported the outcomes of the Camrelizumab Plus Apatinib in Patients with Advanced Cervical Cancer (CLAP) trial on the efficacy and safety of camrelizumab (PD-1 inhibitor) combined with apatinib (vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor) in patients with advanced cervical cancer.13 The CLAP trial revealed that camrelizumab plus apatinib had promising antitumor effects in patients with advanced cervical cancer. The gene discussed is KDR; the disease is cervical carcinoma.